The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial
Open accessAbstract
BACKGROUND: Dalazatide is a specific inhibitor of the Kv1.3 potassium channel. The expression and function of Kv1.3 channels are required for the function of chronically activated memory T cells, which have been shown to be key mediators of autoimmune diseases, including psoriasis. OBJECTIVE: The primary objective was to evaluate the safety of repeat doses of dalazatide in adult patients with mild-to-moderate plaque psoriasis. Secondary objectives were to evaluate clinical proof of concept and the effects of dalazatide on mediators of inflammation in the blood and on chronically activated memory T cell populations. METHODS: Patients (n = 24) were randomized 5:5:2 to receive dalazatide at 30 mcg/dose, 60 mcg/dose, or placebo twice weekly by subcutaneous injection (9 doses total). Safety was assessed on the basis of physical and neurological examination and laboratory testing. Clinical assessments included body-surface area affected, Psoriasis Area and Severity Index (PASI), and investigator and patient questionnaires. RESULTS: The most common adverse events were temporary mild (Grade 1) hypoesthesia (n = 20; 75% placebo, 85% dalazatide) and paresthesia (n = 15; 25% placebo, 70% dalazatide) involving the hands, feet, or perioral area. Nine of 10 patients in the 60 mcg/dose group had a reduction in their PASI score between baseline and Day 32, and the mean reduction in PASI score was significant in this group (P < 0.01). Dalazatide treatment reduced the plasma levels of multiple inflammation markers and reduced the expression of T cell activation markers on peripheral blood memory T cells. LIMITATIONS: The study was small and drug treatment was for a short duration (4 weeks). CONCLUSION: This study indicates that dalazatide is generally well tolerated and can improve psoriatic skin lesions by modulating T cell surface and activation marker expression and inhibiting mediators of inflammation in the blood. Larger studies of longer duration are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the only class of Kv1.3 channel blockers that has successfully completed phase Ib studies in humans for psoriasis (ShK analogs) has not been tested in pre-clinical models of AD pathology [53, 54].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“ShK-223 was selected due to its improved stability and > 10,000-fold selectivity for Kv1.3 channels over neuronal Kv channels [53, 54].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Experimental — accuracy not yet measuredIn the citing paper
“Our pre-clinical findings using ShK-223 are of translational importance because a Kv1.3-blocking ShK analog (dalazatide or ShK-186) that is very similar to ShK-223, is the only selective Kv1.3 blocker to have successfully completed early phase human studies for systemic autoimmunity [53].”
From Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schweiger, D., Baufeld, C., Drescher, P., Oltrogge, B., Höpfner, S., Mess, A., Lüttke, J., Rippke, F., Filbry, A., & Max, H. (2013) · Skin Pharmacology and Physiology · doi:10.1159/000348473 · Cited by 1,346
Arican, O., Aral, M., Sasmaz, S., & Ciragil, P. (2005) · Mediators of Inflammation · doi:10.1155/mi.2005.273 · Cited by 805
Psoriasis prevalence among adults in the United States
Rachakonda, T. D., Schupp, C. W., & Armstrong, A. W. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.11.013 · Cited by 783
CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris
Abrams, J. R., Lebwohl, M. G., Guzzo, C. A., Jegasothy, B. V., Goldfarb, M. T., Goffe, B. S., Menter, A., Lowe, N. J., Krueger, G., Brown, M. J., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5857 · Cited by 597
Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes
Ellis, C. N., & Krueger, G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107263450403 · Cited by 582
Guidelines of care for the management of psoriasis and psoriatic arthritis
Menter, A., Korman, N. J., Elmets, C. A., Feldman, S. R., Gelfand, J. M., Gordon, K. B., Gottlieb, A. B., Koo, J. Y. M., Lebwohl, M., Lim, H. W., et al. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.03.027 · Cited by 558
Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases
Beeton, C., Wulff, H., Standifer, N. E., Azam, P., Mullen, K. M., Pennington, M. W., Kolski-Andreaco, A., Wei, E., Grino, A., Counts, D. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605136103 · Cited by 538
The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
Lowes, M. A., Russell, C. B., Martin, D. A., Towne, J. E., & Krueger, J. G. (2013) · Trends in Immunology · doi:10.1016/j.it.2012.11.005 · Cited by 537
Resident memory T cells in human health and disease
Clark, R. A. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010641 · Cited by 446
The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS
Wulff, H., Calabresi, P. A., Allie, R., Yun, S., Pennington, M., Beeton, C., & Chandy, K. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16921 · Cited by 422
Cited by
Rangaraju, S., Dammer, E. B., Raza, S. A., Rathakrishnan, P., Xiao, H., Gao, T., Duong, D. M., Pennington, M. W., Lah, J. J., Seyfried, N. T., et al. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0254-8 · Cited by 430
“3 channels over neuronal Kv channels [53, 54].”
BackgroundSchendel, V., Rash, L. D., Jenner, R. A., & Undheim, E. A. B. (2019) · Toxins · doi:10.3390/toxins11110666 · Cited by 285
“Consequently, toxins have been an important source of molecular tools for dissecting physiological processes [3], and lead molecules for the development of drugs targeting a range of conditions such as chronic pain [4], diabetes [5], cancer [6], stroke [7], and autoimmune disease [8].”
Peptide therapeutics from venom: Current status and potential
Pennington, M. W., Czerwinski, A., & Norton, R. S. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.09.029 · Cited by 278
Antibodies and venom peptides: new modalities for ion channels
Wulff, H., Christophersen, P., Colussi, P., Chandy, K. G., & Yarov-Yarovoy, V. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0013-8 · Cited by 182
Animal toxins — Nature’s evolutionary-refined toolkit for basic research and drug discovery
Herzig, V., Cristofori-Armstrong, B., Israel, M. R., Nixon, S. A., Vetter, I., & King, G. F. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114096 · Cited by 181
Ion channels as therapeutic antibody targets
Hutchings, C. J., Colussi, P. A., & Clark, T. G. (2018) · mAbs · doi:10.1080/19420862.2018.1548232 · Cited by 145
“in numerous preclinical animal models using a variety of small molecule and peptide toxin blockers(104,106-111) and, importantly, in the clinic through the development of the potent venom peptide analog Shk-186 (dalazatide).(113) Kv1.”
BackgroundMaezawa, I., Nguyen, H. M., Di Lucente, J., Jenkins, D. P., Singh, V., Hilt, S., Kim, K., Rangaraju, S., Levey, A. I., Wulff, H., et al. (2018) · Brain · doi:10.1093/brain/awx346 · Cited by 125
“PAP-1 has further completed IND (Investigational New Drug)- enabling toxicity studies, while ShK-186 has passed both IND toxicity studies and phase 1 safety studies without any adverse findings and has demonstrated efficacy in a small phase 1b study in plaque psoriasis (Tarcha et al., 2017).”
BackgroundSea Anemones: Quiet Achievers in the Field of Peptide Toxins
Prentis, P. J., Pavasovic, A., & Norton, R. S. (2018) · Toxins · doi:10.3390/toxins10010036 · Cited by 128
“The Phase 1b trial in mild-to-moderate plaque psoriasis patients showed that dalazatide was well tolerated and reduced psoriatic skin lesions [59].”
BackgroundVenom peptides as therapeutics: advances, challenges and the future of venom-peptide discovery
Robinson, S. D., Undheim, E. A. B., Ueberheide, B. M., & King, G. F. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1377613 · Cited by 113
“currently in clinical trials or preclinical development have the potential to treat a wider range of conditions including cancer [13], stroke [14], and autoimmune disease [15].”
BackgroundCyclic Peptides in Pipeline: What Future for These Great Molecules?
Costa, L., Sousa, E., & Fernandes, C. (2023) · Pharmaceuticals · doi:10.3390/ph16070996 · Cited by 115
Wang, X., Li, G., Guo, J., Zhang, Z., Zhang, S., Zhu, Y., Cheng, J., Yu, L., Ji, Y., & Tao, J. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01393 · Cited by 105
“ShK Stichodactyla helianthus 35 C1–C6, C2–C4, C3–C5 133 pM (Castaneda et al., 1995) Psoriasis (Tarcha et al., 2017); multiple sclerosis (Beeton et al., 2005); ischemic stroke (Peng et al., 2014); Alzheimer’s disease (Peng et al., 2014)”
BackgroundInfluentialMiniproteins as a Powerful Modality in Drug Development
Crook, Z. R., Nairn, N. W., & Olson, J. M. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.12.008 · Cited by 91
Friends or Foes? Emerging Impacts of Biological Toxins
Clark, G. C., Casewell, N. R., Elliott, C. T., Harvey, A. L., Jamieson, A. G., Strong, P. N., & Turner, A. D. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.12.004 · Cited by 86
“Under the trade name Dalazatide, the compound has successfully completed a clinical trial in patients with psoriasis [59].”
BackgroundIon Channels and Transporters in Inflammation: Special Focus on TRP Channels and TRPC6
Ramirez, G. A., Coletto, L. A., Sciorati, C., Bozzolo, E. P., Manunta, P., Rovere, P. Q., & Manfredi, A. A. (2018) · Cells · doi:10.3390/cells7070070 · Cited by 77
Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke
Chen, Y., Nguyen, H. M., Maezawa, I., Jin, L., & Wulff, H. (2017) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.513 · Cited by 70
“PAP-1 has further completed INDenabling toxicity studies, while ShK-186 has passed both IND toxicity studies and Phase-1 safety studies without any adverse findings.(6,9) In conclusion, we are proposing Kv1.”
BackgroundMethodThe voltage-gated potassium channel KV1.3 as a therapeutic target for venom-derived peptides
Tajti, G., Wai, D. C. C., Panyi, G., & Norton, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114146 · Cited by 64
Schlöder, J., Shahneh, F. Z., Schneider, F.-J., & Wieschendorf, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.973813 · Cited by 67
Discovery of KV1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges
Gubič, Š., Hendrickx, L. A., Toplak, Ž., Sterle, M., Peigneur, S., Tomašič, T., Pardo, L. A., Tytgat, J., Zega, A., & Mašič, L. P. (2021) · Medicinal Research Reviews · doi:10.1002/med.21800 · Cited by 61
Rearrangement of a unique Kv1.3 selectivity filter conformation upon binding of a drug
Tyagi, A., Ahmed, T. U., Jian, S., Bajaj, S., Ong, S. T., Goay, S. S. M., Zhao, Y., Vorobyov, I. V., Tian, C., Chandy, K. G., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113536119 · Cited by 52
Madio, B., Peigneur, S., Chin, Y. K. ‐., Hamilton, B. R., Henriques, S. T., Smith, J. J. L., Cristofori‐Armstrong, B., Dekan, Z., Boughton, B. A., Alewood, P. F., et al. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2897-6 · Cited by 50
Sea anemone venom: Ecological interactions and bioactive potential
Menezes, C., & Thakur, N. L. (2022) · Toxicon · doi:10.1016/j.toxicon.2022.01.004 · Cited by 51
Ramesha, S., Rayaprolu, S., Bowen, C. A., Giver, C. R., Bitarafan, S., Nguyen, H. M., Gao, T., Chen, M. J., Nwabueze, N. V., Dammer, E. B., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013545118 · Cited by 52
T Cells in Systemic Lupus Erythematosus
Paredes, J. L., Fernandez‐Ruiz, R., & Niewold, T. B. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.04.005 · Cited by 52
Liao, Q., Feng, Y., Yang, B., & Lee, S. M. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.08.011 · Cited by 50
Contributions of natural products to ion channel pharmacology
Bajaj, S., Ong, S. T., & Chandy, K. G. (2020) · Natural Product Reports · doi:10.1039/c9np00056a · Cited by 45
Transcriptomic Analysis of Four Cerianthid (Cnidaria, Ceriantharia) Venoms
Klompen, A. M. L., Macrander, J., Reitzel, A. M., & Stampar, S. N. (2020) · Marine Drugs · doi:10.3390/md18080413 · Cited by 45
“3 channel blocker isolated from the sun sea anemone (Stichodactyla helianthus) called ShK [31], which completed Phase 1b trials for autoimmune diseases [32,33].”
BackgroundVoltage-gated potassium channel 1.3: A promising molecular target in multiple disease therapy
Cheng, S., Jiang, D., Lan, X., Liu, K., & Fan, C. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116651 · Cited by 45
Animal Venom in Modern Medicine: A Review of Therapeutic Applications
Kim, E., Hwang, D. H., Prakash, R. L. M., Ravi, D. A., Lee, H., Heo, Y., Munawir, A., Seyedian, R., & Kang, C. (2025) · Toxins · doi:10.3390/toxins17080371 · Cited by 42
Venom-derived peptides for breaking through the glass ceiling of drug development
Freuville, L., Matthys, C., Quinton, L., & Gillet, J. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1465459 · Cited by 41
Lai, I. K., Valdearcos, M., Morioka, K., Saxena, S., Feng, X., Li, R., Uchida, Y., An, L., Li, W., Pan, J. Z., et al. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.05.018 · Cited by 38
“3 blocker dalazatide was shown to reduce the severity of plaque psoriasis in a small Phase-Ib study.(23) Possibly, the specific T-cell subsets involved in these autoimmune conditions express Kv1.”
BackgroundStructures of wild-type and H451N mutant human lymphocyte potassium channel KV1.3
Liu, S., Zhao, Y., Dong, H., Xiao, L., Zhang, Y., Yang, Y., Ong, S. T., Chandy, K. G., Zhang, L., & Tian, C. (2021) · Cell Discovery · doi:10.1038/s41421-021-00269-y · Cited by 37
The contribution of ion channels to shaping macrophage behaviour
Selezneva, A. I., Gibb, A. J., & Willis, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.970234 · Cited by 35
“Selective blocker Psoriasis Phase Ib Moderate effect on plaque size, attributed to T cell effects (Tarcha et al., 2017)”
BackgroundFighting rheumatoid arthritis: Kv1.3 as a therapeutic target
Serrano-Albarrás, A., Cirera-Rocosa, S., Sastre, D., Estadella, I., & Felipe, A. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.016 · Cited by 29
Pharmacological blockade of KV1.3 channel as a promising treatment in autoimmune diseases
Cañas, C. A., Castaño-Valencia, S., & Castro‐Herrera, F. (2022) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2022.100146 · Cited by 32
Veytia‐Bucheli, J. I., Jiménez-Vargas, J. M., Melchy-Pérez, E., Sandoval-Hernández, M. A., Possani, L. D., & Rosenstein, Y. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0257-7 · Cited by 34
“plasmatic and TEM inflammation markers, and to improve psoriatic skin lesions from mild to moderate plaque psoriasis patients [13, 16, 75].”
Wang, Y., Zhu, D., Ortiz-Velez, L., Perry, J. L., Pennington, M. W., Hyser, J. M., Britton, R. A., & Beeton, C. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211977120 · Cited by 32
Mitchell, M. L., Tonkin‐Hill, G. Q., Morales, R. A. V., Purcell, A. W., Papenfuss, A. T., & Norton, R. S. (2020) · Marine Biotechnology · doi:10.1007/s10126-020-09945-8 · Cited by 31
“Two peptides in the venom component library, U-AITXOulsp1 and U-AITX-Oulsp2 (Sunanda et al. 2018; Krishnarjuna et al. 2018b), were predicted to be potassium channel blockers based on similarity to ShK/BgK sequence and structures (Castañeda et al. 1995; Tudor et al. 1996).”
MethodThe Kv1.3 K+ channel in the immune system and its “precision pharmacology” using peptide toxins
Varga, Z., Tajti, G., & Panyi, G. (2021) · Biologia Futura · doi:10.1007/s42977-021-00071-7 · Cited by 28
Alleviating airway inflammation by inhibiting ERK-NF-κB signaling pathway by blocking Kv1.3 channels
Zhou, Q., Wang, T.-Y., Li, M., & Shang, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.07.009 · Cited by 29
Krishnarjuna, B., MacRaild, C. A., Sunanda, P., Morales, R. A. V., Peigneur, S., Macrander, J., Yu, H. H., Daly, M., Raghothama, S., Dhawan, V., et al. (2017) · Peptides · doi:10.1016/j.peptides.2017.10.001 · Cited by 27
Krishnarjuna, B., Villegas‐Moreno, J., Mitchell, M. L., Csóti, A., Peigneur, S., Amero, C., Pennington, M. W., Tytgat, J., Panyi, G., & Norton, R. S. (2018) · Toxicon · doi:10.1016/j.toxicon.2018.05.006 · Cited by 27
Modulating ion channel function with antibodies and nanobodies
Stortelers, C., Pinto-Espinoza, C., Hoorick, D. V., & Koch‐Nolte, F. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.02.003 · Cited by 30
Liao, Q., Gong, G., Poon, T. C. W., Ang, I. L., Lei, K. M. K., Siu, S. W. I., Wong, C. T. T., Rádis‐Baptista, G., & Lee, S. M. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02456-z · Cited by 27
Ong, S. T., Bajaj, S., Tanner, M. R., Chang, S. C., Krishnarjuna, B., Ng, X. R., Morales, R. A. V., Chen, M. W., Luo, D., Patel, D. J., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00035 · Cited by 26
Recent advances in the pharmacology of voltage-gated ion channels
Mateos, D. L., Harris, B. J., Hernández-González, A., Yarov-Yarovoy, V. M., & Wulff, H. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100090 · Cited by 31
Yang, F., Wang, D.-Y., Tong, Y., Qin, C., Yang, L., Yu, F., Huang, X., Liu, S., Cao, Z., Guo, L., et al. (2019) · Journal of Proteomics · doi:10.1016/j.jprot.2019.103435 · Cited by 25
Utilisation of compounds from venoms in drug discovery
Trim, C. M., Byrne, L. J., & Trim, S. A. (2021) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2021.01.001 · Cited by 25
Immunomodulatory properties of molecules from animal venoms
Minutti-Zanella, C., Gil-Leyva, E. J., & Vergara, I. (2021) · Toxicon · doi:10.1016/j.toxicon.2020.12.018 · Cited by 24
Sunanda, P., Krishnarjuna, B., Peigneur, S., Mitchell, M. L., Estrada, R., Villegas‐Moreno, J., Pennington, M. W., Tytgat, J., & Norton, R. S. (2018) · Peptide Science · doi:10.1002/pep2.24073 · Cited by 26
Kv1.3 in the spotlight for treating immune diseases
Navarro‐Pérez, M., Capera, J., Benavente-Garcia, A., Cassinelli, S., Colomer-Molera, M., & Felipe, A. (2024) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2024.2315021 · Cited by 25
“In a phase 1B study, subcutaneous administration of dalazatide to psoriasis patients proved to be safe and well tolerated while reducing T-cell activation and inflammation [165].”
BackgroundInfluentialGao, T., Raza, S. A., Ramesha, S., Nwabueze, N. V., Tomkins, A. J., Cheng, L., Xiao, H., Yepes, M., & Rangaraju, S. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1510-8 · Cited by 24
Paracelsus’ legacy in the faunal realm: Drugs deriving from animal toxins
Fischer, T., & Riedl, R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.10.003 · Cited by 24
Ma, R., & Kwok, H. F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.08.010 · Cited by 25
Why to Study Peptides from Venomous and Poisonous Animals?
de Oliveira, A. L. N., Soares, A. M., & Silva, S. L. D. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10543-0 · Cited by 23
Tanner, M. R., Pennington, M. W., Chauhan, S. S., Laragione, T., Gulko, P. S., & Beeton, C. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1783-9 · Cited by 24
Centipede Venom Peptides Acting on Ion Channels
Chu, Y., Qiu, P., & Yu, R. (2020) · Toxins · doi:10.3390/toxins12040230 · Cited by 22
Chandy, K. G., Sanches, K., & Norton, R. S. (2023) · Channels · doi:10.1080/19336950.2023.2253104 · Cited by 24
Bednenko, J., Harriman, R., Mariën, L., Nguyen, H. M., Agrawal, A., Papoyan, A., Bisharyan, Y., Cardarelli, J., Cassidy-Hanley, D., Clark, T., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1445451 · Cited by 21
Chow, C. Y., Chin, Y. K. ‐., Walker, A. A., Guo, S., Blomster, L. V., Ward, M. J., Herzig, V., Rokyta, D. R., & King, G. F. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00079 · Cited by 24
Cabral, I. M., Gonçalves, C., Grosso, A. R., & Costa, P. M. (2024) · Frontiers in Marine Science · doi:10.3389/fmars.2024.1362697 · Cited by 27
Potential of Venom-Derived Compounds for the Development of New Antimicrobial Agents
Rabea, E. Y., Mahmoud, E. D., Mohamed, N. K., Ansary, E. R., Alrouby, M. R., Shehata, R. R., Mokhtar, Y. Y., Arullampalam, P., Hegazy, A. M., Al-Sabi, A., et al. (2025) · Toxins · doi:10.3390/toxins17050238 · Cited by 23
Unterweger, A., Jensen, M. Ø., Giordanetto, F., Jogini, V., Rüscher, A., Schindler, M., Winkelmann, P., Koletzko, L., Shaw, D. E., Siebeck, M., et al. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab078 · Cited by 20
Ganser, K., Klumpp, L., Bischof, H., Łukowski, R., Eckert, F., & Huber, S. M. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_465 · Cited by 20
Kv1.3 K + Channel Physiology Assessed by Genetic and Pharmacological Modulation
Varanita, T., Angi, B., Scattolini, V., & Szabó, I. (2022) · Physiology · doi:10.1152/physiol.00010.2022 · Cited by 24
Esquinca, M. E. M., Correa, C. N., de Barros, G. M., Montenegro, H., & de Castro, L. M. (2023) · Marine Drugs · doi:10.3390/md21030197 · Cited by 20
Gerdol, M., Cervelli, M., Mariottini, P., Oliverio, M., Dutertre, S., & Modica, M. V. (2019) · Toxins · doi:10.3390/toxins11020106 · Cited by 19
The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion
Chen, Y., Cui, Y., Singh, L., & Wulff, H. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51456 · Cited by 18
Nicolazzo, J. A., Pan, Y., Stefano, I. D., Choy, K. H. C., Reddiar, S. B., Low, Y. L., Wai, D. C. C., Norton, R. S., & Jin, L. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.11.003 · Cited by 19
Bernardes, C. P., Menaldo, D. L., Zoccal, K. F., Boldrini-França, J., Peigneur, S., Arantes, E. C., Rosa, J. C., Faccioli, L. H., Tytgat, J., & Sampaio, S. V. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.08.108 · Cited by 22
Ashwood, L. M., Elnahriry, K. A., Stewart, Z. K., Shafee, T. M. A., Naseem, M. U., Szanto, T. G., van der Burg, C. A., Smith, H. L., Surm, J. M., Undheim, E. A. B., et al. (2023) · BMC Biology · doi:10.1186/s12915-023-01617-y · Cited by 19
Venom back in vogue as a wellspring for drug candidates
McDermott, A. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2004486117 · Cited by 18
Optimization of Pichia pastoris Expression System for High-Level Production of Margatoxin
Naseem, M. U., Tajti, G., Gáspár, A., Szanto, T. G., Borrego, J., & Panyi, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.733610 · Cited by 19
“3 that is under clinical trials for the treatment of multiple autoimmune disorders (Pennington et al., 2015; Tarcha et al., 2017; Tajti et al., 2020; Wang et al., 2020).”
BackgroundDiscovery of novel peptide neurotoxins from sea anemone species
Fu, J., Liao, Y., Jin, A., & Gao, B. (2021) · Frontiers in Bioscience-Landmark · doi:10.52586/5022 · Cited by 18
“An analogue of this peptide (ShK-186) has been developed into the first-in-class clinical candidate dalazatide, and phase I clinical trials have been completed for the treatment of psoriasis [87, 88].”
BackgroundDelgado, A., Benedict, C., Macrander, J., & Daly, M. (2022) · Marine Drugs · doi:10.3390/md20120730 · Cited by 18
“in human trials to combat multiple sclerosis and autoimmune disorders [96,97].”
BackgroundImmune drug discovery from venoms
Jiménez, R. P., Ikonomopoulou, M. P., López, J. A., & Miles, J. J. (2017) · Toxicon · doi:10.1016/j.toxicon.2017.11.006 · Cited by 19
“The clinical trial data has now been published (Tarcha et al., 2017).”
BackgroundInfluentialMapping the chemical and sequence space of the ShKT superfamily
Shafee, T. M. A., Mitchell, M. L., & Norton, R. S. (2019) · Toxicon · doi:10.1016/j.toxicon.2019.04.008 · Cited by 19
Naseem, M. U., Carcamo-Noriega, E. N., Beltrán-Vidal, J., Borrego, J., Szanto, T. G., Zamudio, F. Z., Delgado-Prudencio, G., Possani, L. D., & Panyi, G. (2022) · The Journal of General Physiology · doi:10.1085/jgp.202213146 · Cited by 17
Kim, H., Choi, M., Jeon, S. H., Jang, Y., & Yang, Y. D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052756 · Cited by 19
A common genetic variant rs2821557 in KCNA3 is linked to the severity of multiple sclerosis
Lioudyno, V. I., Abdurasulova, I. N., Negoreeva, I. G., Stoliarov, I., Кудрявцев, И. В., Серебрякова, М. К., Клименко, В. М., & Lioudyno, M. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24596 · Cited by 18
“3 peptide blocker ShK186 (dalazatide) have shown promising results in treating psoriasis as well as systemic lupus nephritis (Chandy & Norton, 2017; Tarcha et al., 2017).”
BackgroundOng, S. T., Tyagi, A., Chandy, K. G., & Bhushan, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.924289 · Cited by 15
“It has advanced to human trials for the treatment of autoimmune and neuroinflammatory disorders (Tarcha et al., 2012; Tarcha et al., 2017; Wulff et al., 2019).”
BackgroundGuo, Q., Fu, J., Yuan, L., Liao, Y., Li, M., Li, X., Yi, B., Zhang, J., & Gao, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-58402-2 · Cited by 19
Smallwood, T. B., Navarro, S., Cristofori‐Armstrong, B., Watkins, T. S., Tungatt, K., Ryan, R. Y. M., Haigh, O. L., Lutzky, V. P., Mulvenna, J. P., Rosengren, K. J., et al. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100834 · Cited by 15
“A derivative of the ShK toxin, dalazatide, has recently undergone a randomized phase 1b trial for the treatment of the autoimmune disease plaque psoriasis (16).”
BackgroundWu, W., An, X., Gong, W., Yang, L., Liu, N., Liu, B., Guo, B., Jiang, Q. Y., & Li, L. (2024) · Advanced Science · doi:10.1002/advs.202406822 · Cited by 26
ShK-Domain-Containing Protein from a Parasitic Nematode Modulates Drosophila melanogaster Immunity
Lima, A. K., Dhillon, H. S., & Dillman, A. R. (2022) · Pathogens · doi:10.3390/pathogens11101094 · Cited by 15
Inoue, M., Tsuji, Y., Yoshimine, C., Enomoto, S., Morita, Y., Osaki, N., Kunishige, M., Miki, M., Amano, S., Yamashita, K., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.012723 · Cited by 12
Identification of WP1066, an inhibitor of JAK2 and STAT3, as a KV1.3 potassium channel blocker
Li, M., & Yu, H. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15441 · Cited by 16
“3 channels at low concentrations, nanomolar or less (Chandy & Norton, 2017; Luna-Ramirez et al., 2020; Tarcha et al., 2017; Wang et al., 2016; Yuan et al., 2018).”
BackgroundInfluentialLintermans, L. L., Stegeman, C. A., Muñoz‐Elías, E. J., Tarcha, E. J., Iadonato, S. P., Rutgers, A., Heeringa, P., & Abdulahad, W. H. (2023) · Lara D. Veeken · doi:10.1093/rheumatology/kead192 · Cited by 11
“Importantly, ShK-186 has completed phase 1 b trial in psoriasis patients, showing the blocker is well tolerated and improves psoriatic skin lesions by inhibiting T cell mediators of inflammation [42].”
BackgroundSelf-citationElnahriry, K. A., Wai, D. C. C., Ashwood, L. M., Naseem, M. U., Szanto, T. G., Guo, S., Panyi, G., Prentis, P. J., & Norton, R. S. (2023) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2023.140952 · Cited by 12
Rogers, M., Obergrussberger, A., Kondratskyi, A., & Fertig, N. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2329104 · Cited by 13
“…is a synthetic version of an ω-conotoxin peptide from cone snails used for pain treatment [113], the K v 1.3 inhibitor Dalazatide sea ane-mone toxin analogue tested in rheumatoid arthritis [114], and XEP-018, a Na V 1.4 blocker inspired by cone snail μ -conotoxin which is used in cosmetics [115].”
BackgroundInfluentialKCNE4-dependent modulation of Kv1.3 pharmacology
Sastre, D., Colomer-Molera, M., de Benito-Bueno, Á., Valenzuela, C., Fernandez-Ballester, G. J., & Felipe, A. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116368 · Cited by 10
Conformational exchange in the potassium channel blocker ShK
Iwakawa, N., Baxter, N. J., Wai, D. C. C., Fowler, N. J., Morales, R. A. V., Sugase, K., Norton, R. S., & Williamson, M. P. (2019) · Scientific Reports · doi:10.1038/s41598-019-55806-3 · Cited by 10
Wang, X., Liao, Q., Chen, H., Gong, G., Siu, S. W. I., Chen, Q., Kam, H., Ung, C. O. L., Cheung, K., Rádis‐Baptista, G., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.763089 · Cited by 11
“An analog of ShK, named ShK-186 or dalazatide, is currently in human clinical trials (Tarcha et al., 2017).”
BackgroundEx silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager
Crook, Z. R., Girard, E. J., Sevilla, G. P., Brusniak, M., Rupert, P. B., Friend, D. J., Gewe, M. M., Clarke, M., Lin, I., Ruff, R. O., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn0402 · Cited by 11
Jin, L., Pan, Y., Pham, A. C., Boyd, B. J., Norton, R. S., & Nicolazzo, J. A. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.10.014 · Cited by 11
Sanches, K., Prypoten, V., Chandy, K. G., Chalmers, D. K., & Norton, R. S. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01237 · Cited by 10
León, M. E. D., Fox, E. G. P., Dunaj, S. J., Jenner, R. A., Keiser, C. N., Macrander, J., Nixon, S. A., Nobile, C. J., Petras, D., Rodríguez‐Román, E., et al. (2025) · Symbiosis · doi:10.1007/s13199-024-01031-0 · Cited by 9
“A synthetic truncated version SHK-186 is a potent and selective blocker of the potassium channel K V 1.4 which has passed Phase 1b clinical trial for plaque psoriasis (Castañeda et al. 1995; Tarcha et al. 2017).”
InfluentialTurcio, R., Matteo, F. D., Capolupo, I., Ciaglia, T., Musella, S., Chio, C. D., Stagno, C., Campiglia, P., Bertamino, A., & Ostacolo, C. (2024) · Marine Drugs · doi:10.3390/md22080350 · Cited by 8
Sanches, K., Wai, D. C. C., & Norton, R. S. (2021) · Toxicon · doi:10.1016/j.toxicon.2021.08.020 · Cited by 8
Overview of protein posttranslational modifications in Arthropoda venoms
Melo‐Braga, M. N., Moreira, R. D. S., Gervásio, J. H. D. B., & Felicori, L. F. (2022) · The Journal of venomous animals and toxins including tropical diseases · doi:10.1590/1678-9199-jvatitd-2021-0047 · Cited by 10
“The improvement in the latter made possible its further application to treat psoriasis, an autoimmune disease, with promising results in the clinical trial [64].”
The next generation of venom‐based drugs
Greener, M. (2020) · Prescriber · doi:10.1002/psb.1837 · Cited by 8
Metadata
- Authors
- Tarcha, E. J., Olsen, C. M., Probst, P., Peckham, D., Muñoz-Elías, E. J., Kruger, J. G., & Iadonato, S. P.
- Affiliations
- Kineta (United States) (US)
- Rockefeller University (US)
- Corresponding author
- Olsen, Chelsea M.
- ORCID
- Olsen, Chelsea M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2017-07-19
- Volume
- 12
- Issue
- 7
- Pages
- e0180762
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5516987
- OpenAlex
- W2737389332
- Cited by
- 167
- References
- 48
- Citations by year
- 2026: 13 · 2025: 16 · 2024: 25 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 18 · 2019: 20 · 2018: 13 · 2017: 6
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Keywords
- plaque psoriasis, memory T cells, drug safety, pharmacodynamics, numbness, paresthesia, inflammatory markers, T cell activation markers, PASI, subcutaneous injection
- MeSH terms
- Adult, Double-Blind Method, Female, Humans, Hypesthesia, Male, Middle Aged, Paresthesia, Proteins, Psoriasis, Treatment Outcome, Potassium Channel Blockers, Kv1.3 Potassium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.